List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Melanoma. 17 results shown below.
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma

Principal Investigator: Sylvia Lee, MD

Study Number: 2643.00

Phase: II



Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
Complete title: RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy followed by Ipilimumab in Metastatic Melanoma

Principal Investigator: Ramesh Rengan

Study Number: 9031

Phase: II



Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Complete title: ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy with Concurrent Nelfinavir and Nivolumab in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma.

Principal Investigator: Ramesh Rengan

Study Number: 9712

Phase: II



A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma
Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-Small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer

Principal Investigator: Sylvia Lee, MD

Study Number: 9103A

Phase: I



Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Julie Park, MD

Study Number: ADVL1412

Phase: I/II



MSB0010718C in Solid Tumors
Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Principal Investigator: Nora Disis, MD

Study Number: 20132079

Phase: I



A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS

Principal Investigator: John Thompson, MD

Study Number: 20150061

Phase: I



A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

Principal Investigator: Laura Chow

Study Number: 20151522

Phase: I



Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Complete title: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: John Thompson, MD

Study Number: 20152783

Phase: I



Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Principal Investigator: Scott Tykodi, MD

Study Number: 20160860

Phase: I/II



Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Principal Investigator: Christina Baik

Study Number: 20161101

Phase: I/II



Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Principal Investigator: John Thompson, MD

Study Number: 20161740

Phase: I



A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
Complete title: A Phase 1/2, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-214 and Anti-PD-L1 (Atezolizumab) or Anti-PD-1 (Nivolumab, Pembrolizumab) in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162818

Phase: I/II



A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers
Complete title: A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Principal Investigator: John Thompson, MD

Study Number: 20170681

Phase: I



An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
Complete title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Principal Investigator: Shailender Bhatia, MD

Study Number: 20170952

Phase: III



A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (WIRB#20142430)

Principal Investigator: Seth Pollack

Study Number: 9290

Phase: I



A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Complete title: SC-4005: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Principal Investigator: Erin Pinto

Study Number: SC-4005

Phase: I/II



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials